Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection - 25/08/11

Doi : 10.1016/j.ajo.2004.05.028

Makoto Inoue, MD ^a,⁎ , Kayoko Takeda, MS ^b, Kunihiko Morita, PhD ^b, Masakazu Yamada, MD ^c, Yusuke Tanigawara, PhD ^b, Yoshihisa Oguchi, MD ^a
^a Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
^b Department of Pharmacy, Keio University Hospital, Tokyo, Japan
^c Division for Vision Research, National Institute of Sensory Organ, National Tokyo Medical Center, Tokyo, Japan.

^*Inquiries to Makoto Inoue, MD, Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo 160–8582, Japan; fax: (+81) 33359-8302

Résumé

Purpose

To compare vitreous concentrations of triamcinolone acetonide (TA) achieved by prior therapeutic intravitreal and subtenon injections.

Design

Interventional case series.

Methods

Vitreous samples were collected from patients who required vitreous surgery, six having received a subtenon injection of TA and another six, an intravitreal injection. Vitreous concentrations of TA were measured by high-performance liquid chromatography.

Results

Vitreous concentrations of TA after intravitreal injection were 1.22 ± 0.24 μg/ml, significantly higher than those after subtenon injection (<0.001 μg/ml, P = .003). Vitreous concentrations of TA after subtenon injection and TA-assisted vitrectomy performed in a few patients to visualize the transparent vitreous gel were 0.20 ± 0.11 μg/ml, an intermediate amount between these two groups.

Conclusion

Much higher vitreous concentrations of TA after intravitreal injection than subtenon injection may accelerate therapeutic effect when intravitreal injections are given to reduce macular edema. Subtenon injections of TA may act via the sclera as opposed to the vitreous.

Le texte complet de cet article est disponible en PDF.